Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Incidence
Sexual disorders are common, occurring in 43% of women and 31% of men in the US.
Epidemiology
Advanced age and co-morbid medical (particularly cardiovascular) and psychiatric conditions are associated with higher rates of sexual dysfunction in both genders. Paraphilic disorders are associated with attention-deficit/hyperactivity disorder (ADHD).
Pathophysiology
Sexual function depends on a complex interplay of biological, social, cultural, and psychological factors, many of which are poorly understood. The human sexual response cycle is a useful framework for understanding sexual problems.
Clinical Findings
The new DSM-5 has introduced substantial changes to the classification of sexual disorders. A careful sexual history remains the most important tool for facilitating diagnosis.
Differential Diagnoses
These include many medical and surgical conditions, adverse effects of medications, and other psychiatric disorders.
Treatment Options
Phosphodiesterase type 5 (PDE-5) inhibitors have revolutionized the treatment of erectile dysfunction and may benefit some women with SSRI-induced sexual dysfunction. Otherwise, pharmacologic options for sexual disorders remain limited, although many are under study, complemented by therapy.
Complications
PDE-5 inhibitors are well-tolerated, although adverse effects, such as headache and low blood pressure, may occur. Hormonal agents used in women are linked to potential risks of cardiovascular disease and breast cancer.
Prognosis
Sexual disorders are often multifaceted and require a multidisclipinary approach to achieve clinically significant improvement.
Sexual disorders are extremely common. It has been estimated that 43% of women and 31% of men in the US suffer from sexual dysfunction. Lack of sexual satisfaction is associated with significant emotional distress (e.g., depression, marital conflict) and physical problems (e.g., cardiovascular disease, diabetes mellitus). Individuals with sexual problems are often reluctant to seek assistance from a physician and may first experiment with any number of self-help methods. However, with the introduction of PDE-5 inhibitors, such as sildenafil (Viagra) for the treatment of erectile dysfunction and the increased interest in pharmacological therapy for female sexual disorders, the frequency of complaints related to sexual dysfunction in primary care practice has risen to nearly 15% to 20% of visits. Nevertheless, the incidence of sexual problems is related to the frequency with which providers take a sexual history.
The new Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), has made several important changes to the classification of sexual disorders. Previously grouped into one chapter, sexual disorders are now separated into three chapters: sexual dysfunctions, paraphilic disorders, and gender dysphoria.
Sexual dysfunction is characterized by a clinically significant disturbance in the ability to respond sexually or to experience sexual pleasure. Previously, it was defined according to the physiological sexual response cycle, a model increasingly felt too simplistic. Criteria are now more precise, requiring 6 months of symptoms and a severity rating. Some disorders are now gender-specific (e.g., male hypoactive sexual desire disorder), and others have been merged (e.g., genito-pelvic pain/penetration disorder instead of vaginismus and dyspareunia), or deleted (e.g., sexual aversion disorder). The sexual dysfunctions are further classified as lifelong or acquired and situational or generalized. The DSM-5 introduces “associated features,” such as relationship and medical factors, which support particular diagnoses.
The DSM-5 for the first time distinguishes between paraphilias and paraphilic disorders. Paraphilias are defined as persistent and intense atypical sexual interests and considered normal. Paraphilic disorders are paraphilias that cause distress or impairment to the individual or that result in personal harm or risk of harm to others.
Finally, gender dysphoria replaces gender identity disorder and describes dissatisfaction with one's natal sex. The concepts are similar; however, gender dysphoria abandons the use of “cross-gender,” allowing for an “alternative” (undefined) gender. All sexual disorders must cause clinically significant distress or an impairment of social function before a diagnosis can be made.
Sexual disorders affect individuals across the epidemiological spectrum. They occur more often in women than in men and are more frequent with advanced age, lower socioeconomic status, obesity, sedentary lifestyle, co-existing medical (e.g., cardiovascular) and psychiatric conditions, and history of sexual trauma. The prototypical paraphilic is young, white, and male and more likely to suffer from ADHD, substance abuse, major depression or dysthymia, and/or a phobic disorder.
Sexual function depends on complex interactions among the brain, hormones, and the vascular system. Neural modulators of sexual desire, arousal, and orgasm include dopamine, melanocortin, estrogen, and testosterone. At the vascular level, nitric oxide (NO) plays a critical role in regulating vaginal smooth muscle tone and intrapenile blood flow. In fact, PDE-5 inhibitors act by prolonging the effects of NO.
The sexual response cycle concept is useful in understanding sexual problems. The stages vary with age and physical status and are affected by medications, diseases, injuries, and psychological conditions ( Table 36-1 ). Three major models have been proposed.
Impaired Sexual Response Phase | Female | Male |
---|---|---|
Desire | Female sexual interest/arousal disorder Other specified sexual dysfunction: sexual aversion |
Male hypoactive sexual desire disorder Other specified sexual dysfunction: sexual aversion |
Excitement (arousal, vascular) | Female sexual interest/arousal disorder | Erectile disorder |
Orgasm (muscular) | Female orgasmic disorder | Delayed ejaculation Premature ejaculation |
Sexual pain | Genito-pelvic pain/penetration disorder | Other specified or unspecified sexual dysfunction |
Masters and Johnson developed the first model of the human sexual response, consisting of a linear progression through four distinct phases: (1) excitement (arousal); (2) plateau (maximal arousal before orgasm); (3) orgasm (rhythmic muscular contractions); and (4) resolution (return to baseline). Following resolution, a refractory period exists in men.
Kaplan modified the Masters and Johnson model by introducing a desire stage (neuropsychological input). The Kaplan model consists of three stages: (1) desire; (2) excitement/arousal; and (3) orgasm (muscular contraction).
Most recently, Basson, recognizing the complexity of the female sexual response, proposed a biopsychosocial model of female sexuality that consists of four overlapping components: (1) biology; (2) psychology; (3) sociocultural factors; and (4) interpersonal relationships. The model acknowledges that many factors may stimulate a woman's receptivity for sex. Indeed, sexual satisfaction may be prompted by such factors as emotional closeness and may still be achieved without direct desire. Additionally, it is known that physical measurements of female arousal (such as increased vaginal secretions) are poorly correlated with sexual satisfaction.
Aging is associated with changes in the normal human sexual response. Men are slower to achieve erections and require more direct genital stimulation. Women have decreased levels of estrogen, leading to decreased vaginal lubrication and narrowing of the vagina. Testosterone levels in both sexes decline with age, which may result in decreased libido.
The diagnosis of a sexual problem relies on a thorough medical and sexual history, supplemented by physical examination and laboratory testing. A mixed organic/psychological basis is often present. Physical disorders, surgical conditions ( Table 36-2 ), medications, and use or abuse of drugs ( Table 36-3 ) can affect sexual function directly or cause secondary psychological reactions that lead to a sexual problem. Psychological factors may predispose to, precipitate, or maintain a sexual disorder ( Box 36-1 ).
Organic Disorders | Sexual Impairment |
---|---|
E ndocrine | |
Hypothyroidism, adrenal dysfunction, hypogonadism, diabetes mellitus | Low libido, impotence, decreased vaginal lubrication, early impotence |
V ascular | |
Hypertension, atherosclerosis, stroke, venous insufficiency, sickle cell disorder | Impotence, but ejaculation and libido intact |
N eurological | |
Spinal cord damage, diabetic neuropathy, herniated lumbar disk, alcoholic neuropathy, multiple sclerosis, temporal lobe epilepsy | Sexual disorder—early sign, low libido (or high libido), impotence, impaired orgasm |
L ocal G enital D isease | |
Male : Priapism, Peyronie's disease, urethritis, prostatitis, hydrocele | Low libido, impotence |
Female : Imperforate hymen, vaginitis, pelvic inflammatory disease, endometriosis | Genito-pelvic pain, low libido, decreased arousal |
S ystemic D ebilitating D isease | |
Renal, pulmonary, or hepatic diseases, advanced malignancies, infections | Low libido, impotence, decreased arousal |
S urgical -P ostoperative S tates | |
Male : Prostatectomy (radical perineal), abdominal-perineal bowel resection | Impotence, no loss of libido, ejaculatory impairment |
Female : Episiotomy, vaginal repair of prolapse, oophorectomy | Genito-pelvic pain, decreased lubrication |
Male and Female : Amputation (leg), colostomy, and ileostomy | Mechanical difficulties in sex, low self-image, fear of odor |
Drug | Sexual Side Effect |
---|---|
C ardiovascular | |
Methyldopa | Low libido, impotence, anorgasmia |
Thiazide diuretics | Low libido, impotence, decreased lubrication |
Clonidine | Impotence, anorgasmia |
Propranolol | Low libido |
Digoxin | Gynecomastia, low libido, impotence |
Clofibrate | Low libido, impotence |
P sychotropics | |
Sedatives | |
Alcohol | Higher doses cause sexual problems |
Barbiturates | Impotence |
Anxiolytics | |
Alprazolam; diazepam | Low libido, delayed ejaculation |
Antipsychotics | |
Thioridazine | Retarded or retrograde ejaculation |
Haloperidol | Low libido, impotence, anorgasmia |
Antidepressants | |
MAOIs (phenelzine) | Impotence, retarded ejaculation, anorgasmia |
Tricyclics (imipramine) | Low libido, impotence, retarded ejaculation |
SSRIs (fluoxetine, sertraline) | Low libido, impotence, retarded ejaculation |
Atypical (trazodone) | Priapism, retarded or retrograde ejaculation |
Lithium Hormones |
Low libido, impotence |
Estrogen | Low libido in men |
Progesterone | Low libido, impotence |
G astrointestinal | |
Cimetidine | Low libido, impotence |
Methantheline bromide | Impotence |
Opiates | Orgasmic dysfunction |
Anticonvulsants | Low libido, impotence, priapism |
Lack of information/experience
Unrealistic expectations
Negative family attitudes to sex
Sexual trauma: rape, incest
Childbirth
Infidelity
Dysfunction in the partner
Interpersonal issues
Family stress
Work stress
Financial problems
Depression
Performance anxiety
Gender dysphoria
The sexual history provides an invaluable opportunity to uncover sexual problems. Patients and physicians alike may be reluctant to discuss sexual problems. Thus, the need to make sexual history-taking a routine part of practice is paramount. Physicians should always attempt to be sensitive and non-judgmental in their interviewing technique, moving from general topics to more specific ones. Questions about sexual function may follow naturally from aspects of the medical history (such as introduction of a new medication, or investigation of a chief complaint that involves a gynecological or urological problem).
Screening questions include: Are you sexually active? With men, women, or both? Is there anything you would like to change about your sex life? Have there been any changes in your sex life? Are you satisfied with your present sex life? To maximize its effectiveness, the sexual history may be tailored to the patient's needs and goals. Physicians should recognize that patients with paraphilic disorders are often secretive about their activities, in part due to legal and societal implications. Patients should be reassured about the confidentiality of their interaction (except in cases where their behavior requires mandatory legal reporting, e.g., as with child abuse).
Clinicians should be aware of the growing numbers of patients with concerns about “hypersexuality” and “sexual addiction,” in part spurred by ease of access to Internet pornography and “cybersex” activities. In fact, a “hypersexual disorder,” conceptualized as a non-paraphilic sexual desire disorder with an impulsivity component, was proposed for DSM-5, although ultimately rejected. Nevertheless, the sexual history-taker should actively explore the role of the Internet in the patient's sexual and non-sexual functioning and the potential for excessive and/or compulsive sexual activities.
While history-taking is often the most important tool in the diagnosis of sexual disorders, the physical examination and pertinent laboratory testing are useful in excluding an organic cause. There is no “routine” work-up. However, special attention should be paid to the endocrine, neurological, vascular, urological, and gynecological systems.
Tests for systemic illness include: complete blood count (CBC), urinalysis, creatinine, lipid profile, thyroid function studies, and fasting blood sugar (FBS). Endocrine studies (including testosterone, prolactin, luteinizing hormone [LH], and follicle-stimulating hormone [FSH]) can be performed to assess low libido and erectile dysfunction. An estrogen level and microscopic examination of a vaginal smear can be used to assess vaginal dryness. Cervical culture and Papanicolaou (Pap) smear can be performed to investigate a diagnosis of dyspareunia. The nocturnal penile tumescence (NPT) test is valuable in the assessment of erectile dysfunction (ED). If NPT occurs regularly (as measured by a Rigi-Scan monitor), problems with erection are unlikely to be organic. Penile plethysmography is used to assess paraphilic disorders by measurement of an individual's sexual arousal in response to visual and auditory stimuli.
Erectile dysfunction (ED) (“impotence”) is characterized by marked difficulty obtaining or maintaining an erection during sexual activity or by a marked decrease in erectile rigidity. Symptoms should be present during 75%–100% of sexual encounters. More than 18 million American men over age 20 suffer from ED, accounting for more than 500,000 ambulatory care visits to health care professionals annually and affecting 40%–50% of men older than 60–70. Between 50% and 85% of cases of ED have an organic basis. Numerous risk factors for ED have been identified ( Box 36-2 ). ED itself may be a symptom of a generalized vascular disease and should prompt further investigation. Depression is a common co-morbidity.
Hypertension
Diabetes mellitus
Smoking
Coronary artery disease
Peripheral vascular disorders
Blood lipid abnormalities
Peyronie's disease
Priapism
Pelvic trauma or surgery
Renal failure and dialysis
Hypogonadism
Alcoholism
Depression
Lack of sexual knowledge
Poor sexual technique
Interpersonal problems
Also known as “retarded ejaculation,” this uncommon disorder is characterized by a marked delay, infrequency, or absence of ejaculation following normal sexual excitement that is not desired by the individual, occurring in 75%–100% of partnered sexual activity. Patients are usually sexually inexperienced men less than 35 years old. Symptoms are usually restricted to failure to reach orgasm in the vagina during intercourse. Delayed ejaculation must be differentiated from retrograde ejaculation, in which the bladder neck does not close off properly during orgasm, causing semen to spurt backward into the bladder. Delayed ejaculation should also be excluded in couples with infertility of unknown cause; the male may not have admitted his lack of ejaculation to his partner. Men with delayed ejaculation report lower levels of sexual arousal and satisfaction despite strong penile response during psychophysiological testing.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here